Precision at the earliest stage of development.
Ordoclin combines dedicated Phase I infrastructure with expertise across pharmacokinetics, pharmacodynamics, and specialized early-phase study designs. Through an integrated model encompassing clinical operations, bioanalytical sciences, biometrics, and regulatory support, studies are executed within a single operational framework designed for efficiency, oversight, and regulatory acceptance.
Let's Connect →Built for complex Phase I development programs.
dedicated Phase-I Beds
Inhalation Chambers
Euglycemic Clamp Devices
BED ICU facility
Experience. Quality. Confidence.
Scientific expertise across key Phase I study models.
Our Phase I clinical trial experience spans a broad range of early-phase study models across multiple development pathways. The following are the Phase I study types conducted by Ordoclin.
Capabilities designed for studies that demand precision and control.
Beyond standard Phase I execution, Ordoclin has invested in specialized infrastructure and scientific expertise that enables studies many CROs cannot accommodate.
Two dedicated negative-air inhalation chambers prevent cross-contamination from airborne drug particles. Extensive experience across MDI, DPI, and nasal delivery — including bronchodilators, inhaled corticosteroids, and combination products. Formoterol, Salbutamol, Fluticasone/Salmeterol, Budesonide/Formoterol
Specialist execution of hyperinsulinemia euglycemic and hyperglycemic clamp studies — including comparative biosimilar insulin PD clamp protocols: validated glucose assessment devices, insulin/glucose assays, and clamp-stable Phase I unit environment.
Comprehensive ECG monitoring capabilities supporting thorough QT/QTc studies in compliance with ICH E14 and associated guidance, with cardiologist oversight throughout.
Appropriately licensed and secured controlled substance study execution, including CNS agents and substances requiring specialist handling and subject monitoring protocols.
Centralized reading by subspecialty-trained radiologists for CNS and retinal imaging endpoints. Modalities include OCT, MRI, PET, CT, FA, and CFP — 10,000+ images reviewed, 600+ clinical sites in the network.
AI-assisted multi-dose pen device studies and human factors self-administration studies were designed and executed by a specialist clinical team with device-specific regulatory expertise.
Regulatory confidence built into every study.
Phase I clinical trials conducted by Ordoclin have supported regulatory submissions across major global markets. Our clinical, bioanalytical, and data management operations are aligned with internationally recognized standards, enabling the generation of clinical data accepted by leading regulatory authorities worldwide.
Phase I studies accepted by:
Phase I clinical trials conducted by Ordoclin have supported regulatory submissions across major global markets. Our clinical, bioanalytical, and data management operations are aligned with internationally recognized standards, enabling the generation of clinical data accepted by leading regulatory authorities worldwide.
Where complexity becomes capability.
Partners choose Ordoclin for its ability to combine scientific expertise, specialized Phase I capabilities, and integrated study execution within a single research environment. Our operational model is designed to support complex development programs while maintaining the oversight, efficiency, and regulatory confidence expected in early-phase clinical research.
